Vor Biopharma Inc. Prepaid Expense, Current
Vor Biopharma Inc. (VOR) had Prepaid Expense, Current of $5.88 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:PrepaidExpenseCurrent · last filed 2026-08-11
- 2026-06-30: Prepaid Expense, Current $5.88M.
- 2026-03-31: Prepaid Expense, Current $6.39M.
- 2025-12-31: Prepaid Expense, Current $1.15M.
- 2025-09-30: Prepaid Expense, Current $747.00K.
| Period end | Prepaid Expense, Current |
|---|---|
| 2026-06-30 | $5.88M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $6.39M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $1.15M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $747.00K 10-Q · filed 2025-11-13 |
| 2025-06-30 | $1.50M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $4.51M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $4.20M 10-K · filed 2026-03-30 |
| 2024-09-30 | $4.20M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $4.05M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $3.83M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $3.15M 10-K · filed 2025-03-20 |
| 2023-09-30 | $3.67M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $3.95M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $6.24M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $4.37M 10-K · filed 2024-03-20 |
| 2022-09-30 | $4.89M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $5.47M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $6.47M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $4.84M 10-K · filed 2023-03-23 |
| 2021-09-30 | $5.36M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $4.57M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $3.61M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $467.00K 10-K · filed 2022-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |